GlassScriptPhysician profile
Seneca Mcgowan
NPI 1366952699
$7,532.86
in general payments reported to CMS, 2019-2025
33 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,141 · 2022: $936 · 2023: $542 · 2024: $1,482 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,593.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,196.23 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $470.75 | 2021-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $354.38 | 2024-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $342.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $295.39 | 2024-2025 | |
| Lilly USA, LLC | $283.06 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Orexo US, INC. | $188.36 | 2023-2024 | Zubsolv |
| Phathom Pharmaceuticals, INC. | $179.09 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.17 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $163.32 | 2021 | |
| Currax Pharmaceuticals LLC | $149.06 | 2021-2022 | |
| Indivior INC. | $137.16 | 2021-2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $121.81 | 2021-2022 | |
| Exact Sciences Corporation | $109.75 | 2024-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $96.88 | 2023-2024 | Brixadi |
| Novartis Pharmaceuticals Corporation | $81.05 | 2021 | |
| Glaxosmithkline, LLC. | $79.53 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $59.17 | 2021 | |
| Alkermes, INC. | $55.57 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $54.01 | 2021-2022 | |
| Astellas Pharma US INC | $48.12 | 2024 | Veozah |
| Verona Pharma, INC. | $47.69 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.97 | 2025 | Jardiance |
| Dynavax Technologies Corporation | $41.93 | 2025 | Heplisav-B |
| Neurocrine Biosciences, INC. | $36.14 | 2022-2024 | Ingrezza |
| Uswm, LLC | $34.44 | 2023 | Lucemyra, Zimhi |
| Lundbeck LLC | $20.01 | 2024 | Rexulti |
| Abbott Laboratories | $18.44 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $18.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.80 | 2024 | |
| Sunovion Pharmaceuticals INC. | $15.69 | 2022 | |
| Amarin Pharma, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seneca Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.